抗体片段市场规模、份额和成长分析（按特异性、片段类型、应用、最终用途和地区划分）－2025-2032年产业预测

预计到 2023 年，全球抗体片段市场规模将达到 72 亿美元，到 2024 年将达到 76.2 亿美元，到 2032 年将达到 119.6 亿美元，预测期（2025-2032 年）的复合年增长率为 5.8%。

在对标靶高效治疗方法和诊断方法日益增长的需求推动下，抗体片段市场正迅速崛起，成为生物学领域的重要组成部分。这些片段以多种形式存在，例如Fab片段、单链可变区片段（scFv）和奈米抗体，与传统单株抗体相比具有显着优势。蛋白质工程、展示技术和计算设计的进步提高了这些片段的稳定性、结合能力和可生产性。随着对创新治疗方法的需求不断增长，抗体片段作为双特异性抗体、抗体药物复合体（CAR）构建体，尤其是在肿瘤学和罕见疾病领域，正日益受到重视。其快速清除和特异性也使其在诊断、影像和个人化医疗等领域具有应用前景，进一步推动了市场扩张。

全球抗体片段市场驱动因素

全球抗体片段市场的主要驱动因素之一是针对包括癌症和自体免疫免疫疾病在内的各种疾病的标靶治疗需求不断增长。对癌症生物学认识的不断深入推动了对更精准、更有效治疗方法的需求，进而引发了人们对单链可变区片段（scFv）和双特异性抗体等抗体片段的浓厚兴趣。与全长抗体相比，这些片段具有许多优势，例如体积较小、组织渗透性较强、免疫抗原性较低。此外，它们在药物研发中的多功能性以及联合治疗的潜力也是推动市场扩张的重要因素。

限制全球抗体片段市场的因素

全球抗体片段市场的主要限制因素之一是此类特殊疗法研发成本高成本。抗体设计的复杂性以及临床试验严格的监管要求需要大量资金投入，这可能会限制中小型生物技术公司的进入，并扼杀创新。此外，成熟製药公司拥有强大的研发管线，竞争格局也对寻求市场份额的新参与企业构成挑战。这些因素可能会阻碍市场成长，降低抗体片段疗法的整体可及性，从而威胁到标靶治疗的发展。

全球抗体片段市场趋势

全球抗体片段市场正经历显着成长，尤其是在肿瘤学和诊断领域。这一趋势主要得益于抗体片段的日益普及。抗体片段具有优异的肿瘤穿透性和快速的循环清除特性，使其成为放射性标记后造影剂和标靶治疗的理想选择。基于片段的偶联物和双特异性抗体正受到越来越多的关注，研究人员和开发人员致力于利用模组化设计来提高治疗效果，同时最大限度地减少脱靶效应。这种创新方法不仅提高了癌症治疗的精准度，也促进了抗体片段在各种治疗和诊断应用中的进一步探索，从而推动了市场扩张。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2024）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术评估
• 监管环境

抗体片段市场规模：特异性及复合年增长率（2025-2032）

• 市场概览
• 单株抗体片段
• 多株抗体片段

抗体片段市场规模（以片段类型划分）及复合年增长率（2025-2032 年）

• 市场概览
• Fab片段
• scFv（单链可变片段）
• 单域抗体（sdAb）
• 其他的

抗体片段市场规模：依应用及复合年增长率（2025-2032 年）

• 市场概览
• 治疗药物
• 诊断
• 研究工具和套件

抗体片段市场规模：依最终用途和复合年增长率划分（2025-2032 年）

• 市场概览
• 肿瘤学
• 免疫学/自体免疫疾病
• 感染疾病
• 其他的

抗体片段市场规模及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2024 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2024 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2022-2024年营收年比比较

主要企业简介

• Pfizer Inc.
• Novartis AG
• Roche Holding AG
• AbbVie Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson
• Amgen Inc.
• Merck KGaA
• Genentech, Inc.
• Ablynx（Sanofi）
• Eli Lilly and Company
• Akeso, Inc.
• Taisho Pharmaceutical Co., Ltd.
• MacroGenics, Inc.
• Harpoon Therapeutics, Inc.
• Chengdu Huasun Technology Group Inc.
• Thermo Fisher Scientific Inc.
• Sartorius AG
• Abcam plc
• Genscript Biotech Corporation

结论与建议

Global Antibody Fragments Market size was valued at USD 7.2 billion in 2023 and is poised to grow from USD 7.62 billion in 2024 to USD 11.96 billion by 2032, growing at a CAGR of 5.8% during the forecast period (2025-2032).

The antibody fragments market is emerging as a vital segment within the broader biological arena, fueled by the rising need for targeted and efficient therapeutics and diagnostics. With various formats such as Fab fragments, single-chain variable fragments (scFv), and nanobodies, these fragments offer substantial benefits over traditional monoclonal antibodies. Advances in protein engineering, display technologies, and computational design are enhancing the stability, binding, and manufacturability of these fragments. As demand for innovative therapeutic options grows, antibody fragments are increasingly recognized as foundational elements for bispecifics, antibody-drug conjugates (ADCs), and CAR constructs, particularly in oncology and rare diseases. Their rapid clearance and specificity also make them suitable for diagnostics, imaging, and personalized medicine, further driving market expansion.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Antibody Fragments market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Antibody Fragments Market Segments Analysis

Global Antibody Fragments Market is segmented by Specificity, Fragment Type, Application, End Use and region. Based on Specificity, the market is segmented into Monoclonal Antibody Fragments and Polyclonal Antibody Fragments. Based on Fragment Type, the market is segmented into Fab Fragments, scFv (Single-Chain Variable Fragments), sdAb (Single-Domain Antibodies / Nanobodies) and Others. Based on Application, the market is segmented into Therapeutics, Diagnostics and Research Tools & Kits. Based on End Use, the market is segmented into Oncology, Immunology / Autoimmune Diseases, Infectious Diseases and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Antibody Fragments Market

One key market driver for the global antibody fragments market is the increasing demand for targeted therapies in the treatment of various diseases, including cancer and autoimmune disorders. As the understanding of cancer biology advances, the desire for more precise and effective treatments has led to a surge in interest in antibody fragments, such as single-chain variable fragments (scFvs) and bispecific antibodies. These fragments offer advantages like smaller size, enhanced tissue penetration, and reduced immunogenicity compared to full-length antibodies. Furthermore, their versatility in drug development and potential for combination therapies contribute significantly to the expanding market landscape.

Restraints in the Global Antibody Fragments Market

One of the key market restraints for the global antibody fragments market is the high cost associated with the research and development of these specialized therapeutics. The complexity of antibody engineering and the stringent regulatory requirements for clinical trials necessitate significant financial investment, which can limit the entry of smaller biotech firms and restrict innovation. Additionally, the competitive landscape, featuring established pharmaceutical companies with robust pipelines, poses challenges for new entrants seeking market share. These factors can impede growth and reduce the overall accessibility of antibody fragment-based therapies, hindering advancements in targeted treatment options.

Market Trends of the Global Antibody Fragments Market

The Global Antibody Fragments market is experiencing significant growth, particularly within the oncology and diagnostics sectors. This trend is fueled by the rising adoption of antibody fragments, which offer superior tumor penetration and rapid circulation clearance, making them ideal for both imaging agents and targeted therapies when radiolabeled. The focus on fragment-based conjugates and bispecific antibodies is intensifying, as researchers and developers aim to enhance therapeutic efficacy while minimizing off-target effects through modularity. This innovative approach not only enhances the precision of cancer treatments but also prompts further exploration of antibody fragments in various therapeutic and diagnostic applications, driving market expansion.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Assessment
• Regulatory Landscape

Global Antibody Fragments Market Size by Specificity & CAGR (2025-2032)

• Market Overview
• Monoclonal Antibody Fragments
• Polyclonal Antibody Fragments

Global Antibody Fragments Market Size by Fragment Type & CAGR (2025-2032)

• Market Overview
• Fab Fragments
• scFv (Single-Chain Variable Fragments)
• sdAb (Single-Domain Antibodies / Nanobodies)
• Others

Global Antibody Fragments Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutics
• Diagnostics
• Research Tools & Kits

Global Antibody Fragments Market Size by End Use & CAGR (2025-2032)

• Market Overview
• Oncology
• Immunology / Autoimmune Diseases
• Infectious Diseases
• Others

Global Antibody Fragments Market Size & CAGR (2025-2032)

• North America (Specificity, Fragment Type, Application, End Use)
  • US
  • Canada
• Europe (Specificity, Fragment Type, Application, End Use)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Specificity, Fragment Type, Application, End Use)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Specificity, Fragment Type, Application, End Use)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Specificity, Fragment Type, Application, End Use)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genentech, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ablynx (Sanofi)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akeso, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taisho Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Harpoon Therapeutics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chengdu Huasun Technology Group Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abcam plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genscript Biotech Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations